FOLH1 and prostate carcinoma: Furthermore, the study evaluated the nanoparticles in vivo using a mouse model of prostate cancer, where the nanoparticles were injected into mice with two groups of PSMA (-) PC3-Flu and PSMA (+) PC3-Pip.